Closely monitor patients by appropriate clinical & laboratory monitoring during treatment; monitor laboratory values on a daily basis. Continue administration only if it is determined that therapeutic benefits outweigh risks. Kidney & liver function tests should be performed daily before & during administration. Carefully monitor for infusion reactions; immediately discontinue administration if any abnormalities are observed. Not recommended for adults, infants, childn & adolescents w/ eGFR <30 mL/min/1.73 m2
& term newborns (7-28 days) w/ serum creatinine levels ≥1 mg/dL; patients w/ ALT levels ≥5 times the upper limit of normal range. Should only be administered in patients w/ ALT levels <5 times the upper limit of normal range if therapeutic benefits outweigh risks. Pregnancy & lactation.